A deep dive into LINCOLN Pharmaceuticals (LINCOPH) — examining the financials, valuation picture, and who owns the stock.
Lincoln Pharma Revenue Trend
At ₹623 Cr, LINCOLN Pharmaceuticals's FY2025 revenue was 7.4% ahead of the ₹581 Cr posted in FY2024.
The 10-year revenue CAGR of 8.9% reflects steady — if not spectacular — top-line expansion from ₹266 Cr to ₹623 Cr.
At ₹623 Cr in annual revenue, LINCOLN Pharmaceuticals is one of the smaller players in the pharmaceuticals space.
Looking at the year-on-year numbers, LINCOLN Pharmaceuticals has seen 8 years of unbroken revenue growth.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹623 Cr | +7.4% |
| FY2024 | ₹581 Cr | +13.8% |
| FY2023 | ₹510 Cr | +8.1% |
| FY2022 | ₹472 Cr | +11.3% |
| FY2021 | ₹424 Cr | — |
View LINCOLN Pharmaceuticals's full 10-year revenue trend with CAGR analysis →
Lincoln Pharma Profitability
Profitability was under pressure with net income dropping 11.7% to ₹82.3 Cr in FY2025.
Net margin thinned to 13.2% in FY2025, compared to 16.1% the year before.
Diluted EPS stood at ₹41.11 in FY2025, compared to ₹46.58 in FY2024.
Is Lincoln Pharma Undervalued
Per the P/E Ratio model, LINCOLN Pharmaceuticals has an estimated intrinsic value of ₹501 (21.1% downside).
LINCOLN Pharmaceuticals shares are currently trading at ₹635.05.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹501 | 21.1% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for LINCOLN Pharmaceuticals with detailed assumptions →
Lincoln Pharma Balance Sheet
Proportional view as of 12 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2025 total assets: ₹7.97B (up 13.8% YoY from ₹7.00B).
Top categories: Cash & ST Investments (23.5%), Property, Plant & Equipment (23.3%), Other Assets (22.4%).
Of the ₹7.97B in liabilities and equity, 84.3% is shareholder equity, 0.0% is interest-bearing debt, and 15.7% is operating liabilities. Notable shift: Other Liabilities is up 19.0% YoY (₹339.48M → ₹403.90M).
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 1.87B |
| Receivables | 1.66B |
| Inventories | 786.77M |
| Property, Plant & Equipment | 1.86B |
| Investments | 26,000 |
| Intangibles & Goodwill | 4.40M |
| Other Assets | 1.79B |
| Category | Value |
|---|---|
| Equity | 6.72B |
| Trade Payables | 849.48M |
| Other Liabilities | 403.90M |
Lincoln Pharma at a Glance
What should investors take away from LINCOLN Pharmaceuticals's (LINCOPH) latest numbers? Here's the summary.
Revenue of ₹623 Cr in FY2025, up 7.4% year-over-year.
Long-term revenue has been compounding at 8.9% annually over 10 years.
The company is profitable, with a net margin of 13.2% and net income of ₹82.3 Cr.
The P/E Ratio model implies 21.1% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
There's more to the story. Craytheon's full profile for LINCOLN Pharmaceuticals includes three valuation models, decade-long financials, and insider activity.